AbbVie, IGI sign licensing deal for cancer drug ISB 2001
AbbVie gains exclusive rights to develop, manufacture, and commercialise ISB 2001 across North America, Europe, Japan, and Greater China.
News
EC approves Tevimbra plus chemo to treat nasopharyngeal cancer
Bayer’s elinzanetant receives UK approval for menopause symptoms
Merck to acquire UK drugmaker Verona Pharma for $10bn
Zentiva, Lupin collaborate on commercialising Certolizumab Pegol
FDA approves Lilly’s revised Alzheimer’s dosing regimen for Kisunla
Sironax grants Novartis exclusive option to acquire its brain delivery platform
Swissmedic approves Norgine’s IFINWIL for paediatric HRNB
